Back to Search Results

3/1/2016

Management of Second Trimester Fetal Loss

Author: Vanessa Torbenson, MD

Registered users can also download a PDF or listen to a podcast of this Pearl.
Log in now, or create a free account to access bonus Pearls features.

Mentor:  Abimbola Famuyide, MD

Editor:    Regan Theiler, MD

 

Second trimester fetal loss occurs between 14 and 27 weeks and may encompass spontaneous abortion, stillbirth, and early preterm labor.  It complicates 1-2% of pregnancies and has been associated with black race, nulliparity, advanced maternal age, and obesity.

Specific causes can be either maternal or fetal; however, in 50% of cases no direct cause is found.  Fetal causes include chromosomal and congenital abnormalities.  Maternal causes include anatomic factors (insufficient cervix and uterine anomalies), immunologic factors, placental abnormalities, infection, thrombophilia and uncontrolled maternal illness.

Most cases of second trimester loss will be diagnosed by ultrasonography.  Further investigation may include amniocentesis, fetal karyotyping, and autopsy. Painless, spontaneous cervical dilation (with our without membrane protrusion), is consistent with cervical insufficiency and is diagnosed by history and physical examination.

Delivery should be initiated soon after the diagnosis of fetal loss to decrease risk of  DIC.  Delivery options are dilatation and evacuation (D&E) or medical induction of labor.  D&E is associated with lower morbidity because of decreased need for antibiotic therapy or further surgical intervention.

Providers should only offer D&E if they are skilled in the procedure and the fetal size is appropriate.  Risks include hemorrhage, uterine perforation and cervical laceration.  D&E does not allow for the patient to view or hold an intact fetus or have an autopsy performed, though a diagnosis may frequently be possible from pathologic analysis.

Oral mifepristone 200 mg followed by misoprostol is the most effective regimen for medical induction with a 24 hour expulsion rate of 91%.  Vaginal misoprostol alone is also very effective.  Doses range from 100 to 600 mcg every 3-12 hours with a maximum cumulative dose of 1400 mcg in 24 hours.  High dose oxytocin is a third, but less effective, option.

Patients with a history of one cesarean may be safely induced with misoprostol with 0.28-0.4% risk of uterine rupture.  Safety data in women with a history of more than one cesarean delivery induced with misoprostol showed no uterine ruptures.

Patients with placenta previa may be induced with misoprostol up to 24 weeks or undergo D&E.  Women with abnormal placentation and a previous cesarean are best treated with D&E due to risk of possible accreta.

Retained placenta complicates up to 50% of misoprostol inductions.  Ten units of IM oxytocin has a 90% expulsion rate within 60 minutes of administration.  When oxytocin is ineffective, carboprost 250ug every 20 minutes for 3 doses and misoprostol 600ug orally or 800ug rectally are effective secondary options.  Caution must be used in patients with asthma and hypertension.  Surgical removal is indicated if the placenta is undelivered after 4 hours. After delivery, mothers should be given the opportunity to bond with the fetus where possible and if requested.  Close follow up is recommended to assess grief response.

Interim evaluation of patients includes pelvic ultrasonography to evaluate uterine anatomy and serum testing for anti-phospholipid antibodies and inherited thrombophilias.  Evaluation results are used to assess risk of recurrence and need for intervention during the next pregnancy.

 

Further Reading:

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 102. Management of stillbirth. Obstet Gynecol. 2009 Mar;113(3):748-61. doi: 10.1097/AOG.0b013e31819e9ee2.

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 135: Second-trimester abortionObstet Gynecol. 2013 Jun;121(6):1394-406. doi: 10.1097/01.AOG.0000431056.79334.cc.

Initial Approval January 2016, Revised July 2017, January 2019

 

********** Notice Regarding Use ************

The Foundation for Exxcellence in Women’s Health, Inc (“Foundation”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.

This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.

Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The Foundation reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. The Foundation does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither the Foundation, the ABOG, SASGOG nor their respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

Copyright 2019 The Foundation for Exxcellence in Women's Health, Inc. All rights reserved.  No re-print, duplication or posting allowed without prior written consent.

Back to Search Results